Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Sharsti L. Sandall, Marsha Mason, Devra Olson, Rebecca Mazahreh, Tom Pires, Disha Sahetya, Lori Westendorf, Chris Leiske, Brian Schimpf, Liem Nguyen, Madhu Katepalli, Esther Trueblood, Christopher Hale, Albina Nesterova, Jason Wall and Timothy S. Lewis
Title SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors
Abstract Text Cancer Res 2019;79(13 Suppl):Abstract nr 2688


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
SGN-CD228A SGNCD228A|SGN CD228A SGN-CD228A is an antibody-drug conjugate comprising a CD228 monoclonal antibody linked to eight molecules of the anti-microtubule compound MMAE, which delivers the cytotoxic agent to CD228-expressing tumor cells, potentially resulting in delayed tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2688).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown melanoma not applicable SGN-CD228A Preclinical - Cell line xenograft Actionable In a preclinical study, SGN-CD228A treatment delayed tumor growth and resulted in complete responses in cell line xenograft models of melanoma (Cancer Res 2019;79(13 Suppl):Abstract nr 2688). detail...
Unknown unknown lung non-small cell carcinoma not applicable SGN-CD228A Preclinical - Pdx Actionable In a preclinical study, SGN-CD228A treatment delayed tumor growth and resulted in complete responses in patient-derived xenograft (PDX) models of non-small cell lung carcinoma (Cancer Res 2019;79(13 Suppl):Abstract nr 2688). detail...